GLP-1 Eligibility Requirements: BMI & Qualifying Conditions

GLP-1 receptor agonists are prescription medicines approved by the FDA for long-term weight management in adults who meet defined body mass index (BMI) and health-condition criteria. They are not approved for cosmetic weight loss, and a BMI number alone does not determine whether someone should start treatment.

This page is written for adults in the United States who are researching whether they meet the criteria before speaking to a clinician — including people sitting just below a threshold, people with a qualifying condition they may not have recognised, and people whose insurance has already declined a request.

By the end you will know the exact BMI numbers used, which health conditions count as qualifying comorbidities and which typically do not, the conditions that rule treatment out entirely, and how coverage rules differ from the FDA criteria.

Quick Answer: Who Qualifies for a GLP-1?

Under current FDA labelling, adults generally meet the clinical criteria for a GLP-1 weight-management medicine with a BMI of 30 or above, or a BMI of 27 or above plus at least one weight-related health condition such as high blood pressure, type 2 diabetes, prediabetes, high cholesterol, or obstructive sleep apnea. Meeting these criteria does not guarantee the medicine is appropriate or covered.

The Four Gates: Why "Do I Qualify?" Has More Than One Answer

Most eligibility articles answer only the first question below. In practice, four separate gates decide whether someone actually starts treatment, and people are commonly turned away at gate two or three after clearing gate one.

Understanding this separation is what prevents the most common frustration we see: a person confirms they meet the BMI criteria, assumes approval is automatic, and is then denied on a technicality that had nothing to do with their weight.

On the ZynoxRX platform, the independent licensed physicians who review intake forms assess gates one and two together — the BMI figure and the medical history are reviewed in the same clinical decision, not sequentially.

Gate 1: The FDA BMI Criteria

The FDA-approved weight-management labels use a consistent two-pathway structure for adults.

Pathway A — BMI of 30 or above

A BMI of 30 kg/m² or higher meets the clinical definition of obesity. Under this pathway, no additional health condition is required.

Pathway B — BMI of 27 or above, plus one comorbidity

A BMI between 27 and 29.9 kg/m² meets the definition of overweight. This pathway requires at least one weight-related comorbid condition documented in your medical record.

This structure is consistent across the currently approved products. The pivotal OASIS 4 trial supporting oral semaglutide enrolled adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with one or more weight-related comorbidities (Wharton et al., 2025). Foundayo is likewise indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition (Drugs.com, 2026).

Independent clinical guidance uses the same numbers. The Endocrine Society recommends pharmacotherapy at a BMI ≥ 27 kg/m² with comorbidity or a BMI over 30 kg/m², used as an adjunct to behavioural modification (Endocrine Society, 2015).

What this looks like on the scale

BMI is calculated from height and weight, so the threshold weight differs for every person. Use this table to locate your approximate thresholds before calculating precisely.

Table calculated using the standard imperial BMI formula (weight in pounds × 703 ÷ height in inches²). Figures are rounded to the nearest pound and are a screening reference, not a diagnosis.

Which medicines these criteria apply to

Not every drug people call a "GLP-1" is approved for weight management. The distinction matters because it determines which criteria a prescriber and an insurer will apply.

Two of these are recent additions. The FDA approved Wegovy tablets in December 2025 as the first oral GLP-1 receptor agonist for obesity (Gastroenterology Advisor, 2026). Foundayo (orforglipron) followed in April 2026 as a once-daily oral option that can be taken at any time of day without restrictions on food and water intake (Eli Lilly, 2026).

Ozempic and Mounjaro contain the same active ingredients as Wegovy and Zepbound but are approved for type 2 diabetes. Prescribing them purely for weight loss is off-label, and most plans will decline to cover it on that basis.

Which Health Conditions Count as Qualifying Comorbidities?

This is the single most searched sub-question on this topic, and the honest answer has three tiers.

Tier 1 — Named on the labels and almost always accepted

• Type 2 diabetes

• Hypertension (high blood pressure)

• Dyslipidaemia (high cholesterol or high triglycerides)

• Obstructive sleep apnea

• Established cardiovascular disease

Tier 2 — Widely accepted in clinical practice, usually accepted by payers

• Prediabetes (elevated HbA1c or impaired fasting glucose)

• Metabolic dysfunction–associated steatotic liver disease (formerly NAFLD/NASH)

• Weight-related osteoarthritis, particularly of the knee or hip

• Polycystic ovary syndrome (PCOS)

• Gastro-oesophageal reflux disease attributed to excess weight

Tier 3 — Frequently submitted, frequently rejected on their own

• Fatigue, low energy, or reduced mobility without a diagnosis

• Family history of diabetes or heart disease without a personal diagnosis

• Prior weight-loss attempts alone

• Body-image concerns or a cosmetic goal

The practical rule: a comorbidity qualifies when it exists as a documented diagnosis in your medical record, not as a symptom you describe. A person with an HbA1c of 6.0% who has never been told they have prediabetes usually has the qualifying condition — it simply has not been coded yet. This is the most recoverable reason for a declined request, and it is fixed with a lab panel and a diagnosis code rather than an appeal.

For a full breakdown of how each condition is documented, see our guide to weight-related health conditions that qualify for GLP-1 treatment.

Can You Qualify With a BMI Under 27?

Under the FDA-approved weight-management labels, no. The label floor for adults is a BMI of 27 with a comorbidity. There is no approved pathway below that number for weight management.

Three nuances are worth knowing, because they explain why this answer is not as absolute as it sounds.

Ethnicity-adjusted thresholds. Cardiometabolic risk appears at lower BMI values in some populations. Guidelines note that while a BMI of at least 25 kg/m² in any patient prompts further evaluation, a BMI of at least 23 kg/m² may warrant evaluation in patients of South Asian, Southeast Asian, and East Asian genetic heredity, as health risks associated with overweight and obesity typically appear at lower BMIs in these populations (AJMC, 2024). The AACE 2025 consensus algorithm applies ethnic-specific cutoffs for BMI and adipose distribution as part of the anthropometric diagnosis (Endocrine Practice, 2025). This affects how a clinician interprets your risk — it does not change the FDA label floor.

BMI is an imperfect screen. An analysis of NHANES data found that 36% of individuals with metabolic syndrome may not be eligible for obesity pharmacotherapy under current BMI treatment criteria (Pham et al., 2024). Waist circumference, body composition, and lab results give a fuller picture, which is why a clinician may recommend other interventions rather than simply declining.

Peak BMI may be what counts. If you previously had a BMI of 32 and have since reduced it to 28, many reviewers consider your highest documented BMI at the point treatment began. Medicare's demonstration programme makes this explicit, as described below.

If your BMI is below the threshold, a clinician can still address the underlying metabolic picture. The appropriate response is a clinical evaluation, not a workaround.

Is There an Age Limit?

Lower limit. The approved weight-management indications are primarily for adults aged 18 and over. Some products carry adolescent indications — Wegovy and Saxenda have approved uses in patients aged 12 and older who meet BMI-percentile criteria, while other products remain adults-only. Adolescent treatment requires paediatric-specific assessment and is outside the scope of telehealth intake in most cases.

Upper limit. There is no upper age cut-off in the FDA labels. Age becomes a clinical consideration rather than an eligibility barrier: older adults may have a higher risk of muscle-mass loss, dehydration, and drug interactions, so clinicians typically monitor more closely and titrate more slowly. Coverage is a separate matter, covered next.

Gate 3: Insurance and Medicare Criteria

Payer criteria are routinely stricter than the FDA label. Common additional requirements include a minimum BMI of 35 or 40, documented participation in a supervised lifestyle programme for three to six months, a trial of a lower-cost medicine first, and re-authorisation contingent on achieving a defined percentage of weight loss.

The Medicare GLP-1 Bridge — new for 2026

Medicare Part D has historically excluded medicines used solely for weight loss. That changed with a time-limited CMS demonstration. The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027 (CMS, 2026).

Its clinical criteria are structured differently from the FDA label, and are stricter. To qualify, a provider must attest that the beneficiary is at least 18 years of age and has a BMI of 35 or above at the time of initiating GLP-1 therapy; or a BMI of 30 or above with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above; or a BMI of 27 or above with prediabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease (CMS, 2026).

Three details are widely misunderstood:

1. BMI is assessed at the point therapy began, not today. Someone who started at a BMI of 37 and is now at 34 is assessed against the BMI ≥ 35 criterion they met at initiation.

2. Some diagnoses route you elsewhere. Type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH are covered under standard Part D, so beneficiaries with those diagnoses obtain GLP-1s through their plan instead.

3. There is no appeals process. A prescriber may resubmit a corrected prior-authorisation form, but the demonstration has no formal appeal route — which makes accurate first-time documentation unusually important.

Our guide to GLP-1 insurance coverage and prior authorisation covers appeal letters and documentation for commercial plans.

Gate 4: A Note on Compounded GLP-1 Medications

Compounded semaglutide and tirzepatide are a distinct regulatory category and are not FDA-approved finished drug products. They are not the same as, nor equivalent to, Ozempic, Wegovy, Mounjaro, or Zepbound.

The regulatory position has tightened considerably. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances (FDA, 2026). This followed the resolution of the underlying shortages and the end of enforcement discretion for compounders during 2025.

Anyone considering a compounded product should verify the pharmacy's licensure and 503A or 503B status, and discuss the differences with a licensed prescriber before starting. The FDA criteria described above apply to the approved brand-name products; they are not a certification of any compounded preparation.

Who Should Not Take a GLP-1 Medication

Meeting the BMI criteria does not make a GLP-1 appropriate. The following are established contraindications and cautions drawn from the approved prescribing information. This list is the minimum — your prescriber will apply additional treatment-specific criteria.

Absolute contraindications

• Personal or family history of medullary thyroid carcinoma (MTC). Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (Eli Lilly, n.d.). The same contraindication applies to semaglutide products.

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

• Serious hypersensitivity to the active ingredient or any excipient.

• Pregnancy. GLP-1 medicines are not recommended during pregnancy. State this to your clinician explicitly rather than assuming it will be asked — and discuss contraception if you may become pregnant, since weight loss can restore fertility.

• Breastfeeding. Use is generally not recommended while nursing.

Conditions requiring evaluation before starting

• History of pancreatitis

• Active gallbladder disease

• Severe gastrointestinal disease, including gastroparesis

• Diabetic retinopathy in patients with type 2 diabetes

• Significant kidney impairment

• Type 1 diabetes (these medicines are not a substitute for insulin)

• Current or past eating disorder

• Concurrent use of another GLP-1 receptor agonist — combining products is not recommended

• Planned surgery or a procedure requiring anaesthesia in the near term

Why the medical-history review is not a formality

A BMI figure cannot reveal a family history of thyroid cancer, a pancreatitis episode years ago, an interaction with a medicine you already take, or a thyroid disorder driving the weight change. These are the findings that alter the recommendation, and they only surface in a structured history review.

The physicians on the ZynoxRX platform decline requests at this stage regularly, including from people who clearly met the BMI criteria. That outcome is the system working as intended.

For a fuller breakdown, see our guide to GLP-1 contraindications and safety screening.

What to Prepare Before Your Assessment

Bringing the right information forward shortens the process and reduces avoidable declines.

1. Current height and weight, measured rather than estimated.

2. Recent lab results — HbA1c, fasting glucose, and a lipid panel are the three that most often establish a qualifying comorbidity.

3. A list of existing diagnoses, including any recorded as "borderline" or "elevated."

4. A complete medication and supplement list, including insulin or sulfonylureas if you have diabetes.

5. Family history, specifically thyroid cancer and endocrine conditions.

6. Your highest documented weight and the date, if you have lost weight recently.

7. Any prior denial letter, which usually names the exact criterion that was not met.

Medical Disclaimer

The information provided on this page is for educational purposes only and does not constitute medical advice. Individual results may vary. Eligibility criteria described here are summarised from FDA-approved prescribing information and public payer policy and may change. Please consult a qualified medical practitioner before undergoing any medical treatment to determine if it is suitable for your specific health condition and concerns. If you have a personal or family history of medullary thyroid carcinoma or MEN 2, are pregnant, or are breastfeeding, tell your clinician before any assessment.

Frequently Asked Questions

Can I qualify with a BMI under 27?

Not under the current FDA-approved weight-management labels, which set the adult floor at a BMI of 27 with at least one qualifying condition. Clinicians may interpret risk differently for patients of Asian heritage, where cardiometabolic risk appears at lower BMI values, but this does not change the approved label threshold. A clinician can still evaluate and treat the underlying metabolic issues.

Which health conditions count as comorbidities?

Type 2 diabetes, hypertension, high cholesterol or triglycerides, obstructive sleep apnea, and established cardiovascular disease are named on the labels and are the most reliably accepted. Prediabetes, fatty liver disease, weight-related osteoarthritis, and PCOS are commonly accepted in practice. The condition must be a documented diagnosis in your record, not a self-reported symptom.

Is there an age limit for GLP-1 medication?

There is no upper age limit in the FDA labels, though clinicians typically monitor older adults more closely for muscle-mass loss, dehydration, and drug interactions. The lower limit is generally 18, with certain products carrying separate adolescent indications from age 12 that require paediatric-specific assessment.

What conditions disqualify me from GLP-1 treatment?

A personal or family history of medullary thyroid carcinoma, MEN 2, serious hypersensitivity to the active ingredient, pregnancy, and breastfeeding are the principal exclusions. Pancreatitis history, gallbladder disease, gastroparesis, type 1 diabetes, and a current or past eating disorder require evaluation and may rule out treatment depending on the findings.

Do I qualify for Wegovy specifically?

Wegovy's adult weight-management criteria follow the standard structure — a BMI of 30 or above, or 27 or above with at least one weight-related condition — and it is available in both weekly injection and daily tablet form. Whether your plan covers it is a separate question determined by your formulary and prior-authorisation criteria.

Does meeting the BMI criteria mean my insurance will cover it?

No. Payer criteria are frequently stricter than the FDA label and may require a higher BMI, documented lifestyle-programme participation, or a step-therapy trial first. Medicare Part D historically excluded weight-loss medicines; the CMS GLP-1 Bridge demonstration provides a time-limited route with its own separate criteria through December 2027.

What if my BMI dropped below the threshold after I started?

Many reviewers assess BMI at the point treatment was initiated rather than at the time of the request. CMS makes this explicit for its demonstration programme: a beneficiary who began therapy at a BMI of 37 and is now at 34 is assessed against the criterion met at initiation. Keep documentation of your starting weight.

Next Step

If you want to know where you stand against these criteria, the free eligibility assessment takes a few minutes and is reviewed by an independent licensed US physician. There is no obligation, and a decline is a legitimate outcome — the review exists to determine suitability, not to approve.

You can also read more about how the ZynoxRX process works or compare semaglutide and tirzepatide programmes.

References

Centers for Medicare & Medicaid Services. (2026). Medicare GLP-1 Bridge: Information for providers. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers

Drugs.com. (2026). Foundayo (orforglipron) FDA approval history. https://www.drugs.com/history/foundayo.html

Eli Lilly and Company. (2026, April 1). FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

Eli Lilly and Company. (n.d.). Zepbound (tirzepatide) prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdf

Endocrine Society. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. https://www.endocrine.org/clinical-practice-guidelines/pharmacological-management-of-obesity

Garvey, W. T., et al. (2025). American Association of Clinical Endocrinology consensus statement: Algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease — 2025 update. Endocrine Practice. https://www.endocrinepractice.org/article/S1530-891X(25)00977-2/fulltext

Gastroenterology Advisor. (2026). FDA approves oral Wegovy for weight management. https://www.gastroenterologyadvisor.com/news/fda-approves-oral-wegovy-for-weight-management/

Pham, D. D., et al. (2024). Body mass index is a barrier to obesity treatment. National Library of Medicine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324493/

The American Journal of Managed Care. (2024). A review of current guidelines for the treatment of obesity. https://www.ajmc.com/view/review-of-current-guidelines-for-the-treatment-of-obesity

U.S. Food and Drug Administration. (2026, April 30). FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393, 1077–1087. https://doi.org/10.1056/NEJMoa2500969